



Loc 756 BA 2:163 GP(21) #14
1/7/89

JOINT INVENTORS
Docket No.: ORTH 518

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
JAN 17 1989

APPLICANT :Michael P. Wachter et al. CORRESPONDENCE SECTION 89 JAN 10 PM 1:05
SERIAL NO.:42,661 RECEIVED
FILED :April 29, 1987 EXAMINER: R. Ramsue
FOR :PHARMACOLOGICALLY ACTIVE 1,5-DIARYL-3-SUBSTITUTED
PYRAZOLES AND METHOD FOR SYNTHESIZING THE SAME

SUPPLEMENTAL DECLARATION
(Continuation-in-Part - Claims Only)

18-26868-52
We, Michael P. Wachter and Michael P. Ferro, as named inventors in the application for Letters Patent for an improvement in PHARMACOLOGICALLY ACTIVE 1,5-DIARYL-3-SUBSTITUTED-PYRAZOLES AND METHOD FOR SYNTHESIZING THE SAME, Serial No. 42,661, filed in the United States Patent and Trademark Office on or about April 29, 1987, which in part discloses and claims subject matter disclosed in a then pending earlier application Serial No. 867,996, filed on or about May 29, 1986, hereby declare that the subject matter of the following claims, which are all of the claims in said later filed application and which have been amended or presented by amendment(s) dated

July 30, 1987


December 23, 1987

August 25, 1988

was part of the invention of the above-identified applications, that the subject matter of the following claims to the extent that it is common to said earlier application, was invented before the filing date of said earlier application for such invention; that the subject matter of the following claims to the extent that it is not common to said earlier application was invented before the filing date of the later filed application for such invention.

CLAIMS:

Claim 1. A compound having a structure that corresponds to the formula:



wherein R₁ and R₃ are selected from the group consisting of halo, trifluoromethyl, methyl and methoxy.

Claim 2. A compound which is
3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-hydroxy-N-methylpropanamide.

Claim 3. A compound of claim 1 which is
5-(4-chlorophenyl)-3-(3-hydroxypropyl)-1-(4-methoxyphenyl) pyrazole.

Claim 4. A compound of claim 1 which is
5-(4-trifluoromethylphenyl)-3-(3-hydroxypropyl)-1-(4-methoxyphenyl) pyrazole.

Claim 5. A compound of claim 1 which is
1-(4-bromophenyl)-5-(4-chlorophenyl)-3-(3-hydroxypropyl) pyrazole.

Claim 6. A compound which is
3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-tert-
butyl-N-hydroxypropanamide.


Claim 7. A compound which is
N-carboxymethyl-3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-
pyrazolyl]-propanamide.

Claim 8. A compound selected from the group consisting of
3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-
hydroxy-N-isopropylpropanamide, 3-[5-(4-chlorophenyl)-1-
(4-methoxyphenyl)-3-pyrazolyl]-N-cyclohexyl-N-hydroxy-
propanamide, and 3-[5-(4-chlorophenyl)-1-(4-methoxy-phenyl)-3-
pyrazolyl]-N-ethyl-N-hydroxypropanamide.

Claim 9. A compound selected from the group consisting of
3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-hydroxy-
N-phenyl-propanamide, 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-
3-pyrazolyl]propylamine, 3-(5-(4-chlorophenyl)-1-
(4-methoxyphenyl)-3-pyrazolyl]propanal, 5-(4-chlorophenyl)-
3-(3-oximino-propyl)-1-(4-methoxyphenyl)-pyrazole and
3-(3-hydroxypropyl)-1-(4-methoxyphenyl)-5-(4-tolyl)pyrazole.

Claim 10. A pharmaceutical composition for the alleviation
of inflammatory and cardiovascular disorders in mammals for
topical, oral, parental and aerosol administration, comprising
an effective amount of a substituted pyrazole compound of claim
1. as the active ingredient dispersed in a pharmaceutically
acceptable carrier.

Claim 11. A compound having a structure that corresponds to the formula:



wherein

R_1 and R_2 are selected from the group consisting of halo, trifluoromethyl and methyl and X is selected from the group consisting of $-C(O)-R_3$ wherein R_3 is selected from the group consisting of $-N(CH_3)OH$, $-N(t\text{-butyl})OH$, $-N(i\text{-propyl})OH$, $-N(cyclohexyl)OH$, $-N(ethyl)OH$ and $-N(phenyl)OH$ or R_3 is $-NHCH_2CO_2H$, or X is $-CH_2NH_2$, $-C(O)H$ or $-C(=NOH)H$.

Claim 12. A method for alleviating inflammation in a mammal exhibiting an inflammatory response comprising administering to said mammal a pharmaceutical composition according to claim 11.

Claim 13. A method for treating inflammatory conditions of skin, including psoriasis or other dermatitis, comprising administering to said mammal a pharmaceutical composition according to claim 11.

Claim 14. A compound of claim 11 which is 3-[1-(4-methoxyphenyl)-5-(4-methylphenyl)-3-pyrazolyl]-N-hydroxy-N-methyl propanamide.

We hereby state that we have reviewed and understand the contents of the aforesaid claims as amended by the amendment(s) referred to above.

We acknowledge the duty to disclose information which is material to the examination of the above-identified application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereof.

Inventor's Full Name Michael P. Wachter

Michael P. Wachter
(Signature)

Date December 23, 1988

Inventor's Full Name Michael P. Ferro

Michael P. Ferro
(Signature)

Date December 23, 1988

Inventor's Full Name _____

(Signature)

Date _____